Study reveals bone risks from common skin treatment
NCT ID NCT03926377
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looked at 47 people with bullous pemphigoid, a blistering skin condition, who were treated with high-dose topical corticosteroids (clobetasol propionate) for 6 months. Researchers measured bone mineral density at the start, at 3 months, and at 6 months to see if the treatment weakened bones. The goal was to understand the side effects of this standard therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- clobetasol propionate (topical corticosteroid)
- What this could lead to
- If successful, this could help doctors understand the bone health risks of long-term topical steroid use in bullous pemphigoid patients.
- What could go wrong
- This is a small, completed Phase 4 study with only 47 participants, so results may not apply broadly. It measures bone density changes but does not test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BULLOUS PEMPHIGOID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Amiens
Amiens, 80480, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can discarded bone reveal the secrets to stronger bones?
- Could a common diabetes drug weaken your bones?
- A tastier calcium chew might boost bone Health—But does it work?
- Exercise program aims to steady the stance of osteoporosis patients
- Can a Bone-Strengthening infusion given right after hip surgery prevent a second break?
- Can a single dose of zoledronic acid safely treat bone loss in dialysis patients?